Groundbreaking research from the University of Houston reveals that a single low-dose atropine eye drop can produce effects lasting up to 24 hours in managing Myopia. The condition affects nearly one-third of adults in the United States, making effective management strategies increasingly important.
Sustained Functional Changes Without Structural Impact
The study, led by Lisa Ostrin along with researcher Barsha Lal, found that even one drop of low-dose Atropine (0.01%–0.1%) significantly alters pupil size and focusing ability. Notably, these changes persist for at least 24 hours. However, researchers observed no short-term structural changes in the eye, aside from temporary shifts in retinal blood flow.
Insights from Clinical Research
Published in the journal Eye and Vision, the findings build on ongoing work by David Berntsen, who is leading clinical trials on delaying myopia progression in children using atropine drops. While low-dose atropine is already widely prescribed, its immediate effects on the retina and surrounding structures have remained unclear until now.
Evaluating Eye Structure and Blood Flow
To address this gap, the researchers examined how different concentrations of atropine affect key ocular parameters, including eye length, retinal thickness, and choroidal thickness. These factors are critical, as increased eye length is strongly associated with worsening myopia.
As reported by medicalxpress, the team found that a single dose did not alter axial length or tissue thickness within 24 hours. However, it did temporarily influence blood flow in the retina, suggesting a short-term vascular response.
Study Design and Key Observations
In a double-masked, randomized study, 20 healthy adults received either atropine or a placebo in one eye across multiple sessions. Researchers then measured structural and functional changes at one hour and again at 24 hours post-administration. This approach allowed them to capture both immediate and sustained effects.
Advancing Precision in Myopia Care
Importantly, the findings align with earlier research by Ostrin, which showed that atropine also produces measurable short-term changes in pupil dynamics. Together, these studies indicate that atropine primarily triggers functional and vascular responses without altering eye structure in the short term.
As a result, the research strengthens the scientific basis for using atropine in myopia management. By linking measurable eye responses with patient experience, it supports more precise, evidence-based, and individualised treatment strategies.